Anti-tumor activity of the proteasome inhibitor PS-341 in mantle cell lymphoma B cells.

被引：0
|
作者：
Pham, L [1 ]
Tamayo, A [1 ]
Lo, P [1 ]
Yoshimura, L [1 ]
Ford, RJ [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2001年 / 98卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1945
引用
收藏
页码：465A / 465A
页数：1
相关论文
共 50 条
  • [1] Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
    Zou, W
    Yue, P
    Lin, N
    He, M
    Zhou, ZM
    Lonial, S
    Khuri, FR
    Wang, BH
    Sun, SY
    CLINICAL CANCER RESEARCH, 2006, 12 (01) : 273 - 280
  • [2] The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated lysis
    Sayers, TJ
    Brooks, AD
    Seki, N
    Raziuddin, A
    Ma, WH
    Blazar, B
    Elliott, PJ
    Murphy, WJ
    FASEB JOURNAL, 2002, 16 (04): : A669 - A669
  • [3] The synergy effects of proteasome inhibitor PS-341 and TRAIL on the apoptosis of human tumor cells
    Toh, U
    Sayers, TJ
    Seki, N
    Shirouzu, K
    Yamana, H
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 154 - 154
  • [4] The proteasome inhibitor PS-341 induces Cox-2 in murine and human endothelial cells.
    Csizmadia, V
    Rottman, J
    Bouchard, P
    Raczynski, A
    Juedes, M
    White, P
    Sasseville, V
    TOXICOLOGICAL SCIENCES, 2003, 72 : 47 - 47
  • [5] Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341
    Hideshima, T
    Mitsiades, C
    Akiyama, M
    Hayashi, T
    Chauhan, D
    Richardson, P
    Schlossman, R
    Podar, K
    Munshi, NC
    Mitsiades, N
    Anderson, KC
    BLOOD, 2003, 101 (04) : 1530 - 1534
  • [6] The proteasome inhibitor PS-341 sensitizes tumor cells to TRAIL-mediated apoptosis.
    Sayers, TJ
    Brooks, A
    Seki, N
    Murphy, WJ
    Elliott, PJ
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3718S - 3718S
  • [7] The proteasome inhibitor bortezomib (PS-341) inhibits growth and induces apoptosis in primary effusion lymphoma cells
    Matta, H
    Chaudhary, PM
    CANCER BIOLOGY & THERAPY, 2005, 4 (01) : 77 - 82
  • [8] Blockade of Hsp27 overcomes bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells
    Chauhan, D
    Li, GL
    Shringarpure, R
    Podar, K
    Ohtake, Y
    Hideshima, T
    Anderson, KC
    CANCER RESEARCH, 2003, 63 (19) : 6174 - 6177
  • [9] Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, velcade)
    Schumacher, Lana Y.
    Vo, Dan D.
    Garban, Hermes J.
    Comin-Anduix, Begona
    Owens, Sharla K.
    Dissette, Vivian B.
    Glaspy, John A.
    McBride, William H.
    Bonavida, Benjamin
    Economou, James S.
    Ribas, Antoni
    JOURNAL OF IMMUNOLOGY, 2006, 176 (08): : 4757 - 4765
  • [10] The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents
    Ma, MH
    Yang, HH
    Parker, K
    Manyak, S
    Friedman, JM
    Altamirano, C
    Wu, ZQ
    Borad, MJ
    Frantzen, M
    Roussos, E
    Neeser, J
    Mikail, A
    Adams, J
    Sjak-Shie, N
    Vescio, RA
    Berenson, JR
    CLINICAL CANCER RESEARCH, 2003, 9 (03) : 1136 - 1144
12345